GlassScriptPhysician profile
Ahmed Amro
NPI 1952716789
$6,791.91
in general payments reported to CMS, 2019-2025
42 companies · $1,947 in 2025
The $1,947 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $487 · 2021: $1,793 · 2022: $1,453 · 2023: $532 · 2024: $580 · 2025: $1,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,529 · Consulting Fee: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,528.56 |
| Consulting Fee | $530.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,012.06 | 2020-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $943.50 | 2021-2025 | Aveir |
| Teva Pharmaceuticals USA, INC. | $603.64 | 2022 | |
| Stryker Corporation | $601.41 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Flowtriever |
| Boston Scientific Corporation | $481.46 | 2020-2025 | Watchman Flx |
| Inari Medical, INC. | $433.93 | 2022-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novartis Pharmaceuticals Corporation | $297.20 | 2022-2025 | |
| Amgen INC. | $235.25 | 2020-2025 | Repatha, Repatha |
| Pfizer INC. | $224.19 | 2022-2025 | |
| Medtronic, INC. | $223.19 | 2022-2025 | Corevalve Evolut R, Onyx Frontier |
| Cardiovascular Systems INC. | $212.36 | 2021 | |
| Endologix LLC | $198.78 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $165.63 | 2021-2023 | Xarelto |
| Medtronic Vascular, INC. | $144.98 | 2020 | |
| Shockwave Medical, INC | $110.96 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $90.79 | 2023-2025 | Opsumit, Uptravi |
| Scpharmaceuticals INC. | $85.33 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $71.87 | 2021-2025 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $64.67 | 2024 | Arcalyst |
| Imperative Care, INC | $60.50 | 2024-2025 | Symphony Catheter, Prodigy Catheter |
| Heartflow, INC. | $50.74 | 2025 | |
| Abiomed | $46.41 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.08 | 2021 | |
| Alnylam Pharmaceuticals INC. | $40.92 | 2023 | Onpattro |
| Zimmer Biomet Holdings, INC. | $38.06 | 2023 | Sternalock Blu System |
| Novo Nordisk INC | $35.30 | 2022-2024 | Ozempic |
| Teleflex LLC | $28.64 | 2022-2024 | Turnpike |
| Chiesi USA, INC. | $28.17 | 2021-2023 | Cleviprex, Kengreal |
| Bridgebio Pharma, INC. | $20.81 | 2025 | Attruby |
| Cvrx, INC. | $19.35 | 2022-2023 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $18.83 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $17.25 | 2024 | |
| Angiodynamics, INC. | $17.12 | 2021 | |
| Cardiva Medical, INC. | $16.82 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Amarin Pharma, INC. | $16.20 | 2021 | |
| Inspire Medical Systems, INC. | $15.84 | 2024 | Inspire |
| Kiniksa Pharmaceuticals, LTD. | $15.81 | 2023 | Arcalyst |
| Tactile Systems Technology INC | $14.67 | 2025 | Nimbl, Flexitouch Plus |
| Abbvie INC. | $13.52 | 2023 | Vraylar |
| Penumbra, INC. | $12.75 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.42 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Amro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.